EU Postmarket Efficacy Studies To Get More 'Predictability'
This article was originally published in The Pink Sheet Daily
Executive Summary
EMA could issue scientific guideline on PAES for public consultation by November.
You may also be interested in...
Using Enriched Studies For Post-Approval Evidence Needs
These days, clinical trial sponsors are being asked to provide empirical evidence to many stakeholders with diverse needs and to do so efficiently. By taking a holistic view of post-approval evidence needs, it is possible to address many stakeholders’ needs, thereby minimizing expense while increasing the likelihood of getting data that are fit for a variety of purposes.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.